Cidara Therapeutics EBITDA Margin 2014-2022 | CDTX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Cidara Therapeutics (CDTX) over the last 10 years. The current EBITDA margin for Cidara Therapeutics as of September 30, 2022 is .
| Cidara Therapeutics EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-09-30 |
$0.06B |
$-0.03B |
-54.10% |
| 2022-06-30 |
$0.03B |
$-0.07B |
-251.85% |
| 2022-03-31 |
$0.05B |
$-0.04B |
-81.48% |
| 2021-12-31 |
$0.05B |
$-0.04B |
-89.80% |
| 2021-09-30 |
$0.05B |
$-0.05B |
-100.00% |
| 2021-06-30 |
$0.04B |
$-0.05B |
-109.76% |
| 2021-03-31 |
$0.01B |
$-0.07B |
-672.73% |
| 2020-12-31 |
$0.01B |
$-0.07B |
-583.33% |
| 2020-09-30 |
$0.01B |
$-0.07B |
-650.00% |
| 2020-06-30 |
$0.03B |
$-0.05B |
-166.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.127B |
$0.050B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
